Results 101 to 110 of about 1,098,931 (194)

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines [PDF]

, 2009
Background Imatinib mesylate, a selective inhibitor of Abl tyrosine kinase, is efficacious in treating chronic myeloid leukaemia (CML) and Ph+ acute lymphoblastic leukaemia (ALL).
Schwarz, Kerstin, Ruthardt, Martin, Romanski Annette, Romanski, Annette, Ruthardt Martin, Ottmann, Oliver G., Ottmann, Oliver G, Bacic, Biserka, Gwanmesia Patricia, Gwanmesia, Patricia Mambou, Schwarz Kerstin, Ottmann Oliver G, Bacic Biserka   +12 more
core   +1 more source

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

International Journal of Cancer, Volume 159, Issue 6, Page 1499-1509, 15 September 2026.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang, Jia Li, Luming Cao, Ying Zhang, Xin Wan, Xingtong Wang, Yangzhi Zhao, Zhaoxia Li, Chengqian Chen, Yang Song, Ou Bai   +10 more
wiley   +1 more source

B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292

ImmunoTargets and Therapy, 2014
Jon E Arnason,1 Jennifer R Brown21Beth Israel Deaconess Medical Center, 2CLL Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USAAbstract: Chronic lymphocytic leukemia (CLL) is the most common ...
Arnason JE, Brown JR
doaj  

High Throughput Screens Yield Small Molecule Inhibitors of Leishmania CRK3:CYC6 Cyclin-Dependent Kinase [PDF]

, 2011
Background: Leishmania species are parasitic protozoa that have a tightly controlled cell cycle, regulated by cyclin-dependent kinases (CDKs). Cdc2-related kinase 3 (CRK3), an essential CDK in Leishmania and functional orthologue of human CDK1, can form ...
Walker, Roderick G., Brown, Elaine, Thomson, Graeme, Blake, David G., Malone, Kirk, Turner, Nicholas J., Grant, Karen, Mottram, Jeremy C., Walkinshaw, Malcolm D., Nowicki, Matthew W.   +9 more
core   +2 more sources

The Potential Therapeutic Role of Bruton Tyrosine Kinase Inhibition in Neurodegenerative Diseases

Applied Sciences
Bruton Tyrosine Kinase (BTK) has emerged as a critical mediator in the pathophysiology of neuroinflammation associated with neurodegenerative diseases.
Francesco D’Egidio, Housem Kacem, Giorgia Lombardozzi, Michele d’Angelo, Annamaria Cimini, Vanessa Castelli   +5 more
doaj   +1 more source

Protein recruitment to receptor tyrosine kinase-mediated early signalling complexes. [PDF]

, 2007
Receptor tyrosine kinase (RTK) signalling regulates the activation of numerous cellular processes in response to various external stimuli. Spatio-temporal regulation of protein recruitment to activated tyrosine kinase receptors is important for the ...
Schller, A.C.
core  

Review of Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

, 2019
Mantle cell lymphoma (MCL) is a rare subtype of aggressive B-cell non-Hodgkin lymphoma that remains incurable with standard therapy. Patients typically require multiple lines of therapy, and those with relapsed or refractory (R/R) disease have a very ...
A. Christofides, L.H. Sehn, N.L. Berinstein, C. Owen   +3 more
core   +1 more source

Personalized Approach to Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients with Respect to Molecular Landscape: A Case Report and Literature Review

Клиническая онкогематология
The term “Diffuse Large B-Cell Lymphoma” (DLBCL) covers an extremely heterogeneous range of aggressive hematological tumors of lymphoid origin. The recommended standard first-line treatment R-CHOP is still the leading therapy for newly diagnosed DLBCL ...
Marat Albertovich Mingalimov, E. A. Baryakh, T. N. Tolstykh, A. V. Misyurin, L. A. Kesaeva, A. S. Mkrtchyan, A. M. Kovrigina, E. N. Misyurina, M. S. Orlova, T. S. Chudnova, D. D. Ivanova, O. L. Kochneva, S. S. Andreev, K. V. Yatskov, I. V. Samsonova, M. A. Lysenko   +15 more
doaj   +1 more source

Pirtobrutinib for the Treatment of B-Cell Malignancies: Recent Developments

healthbook TIMES. Oncology Hematology
Bruton tyrosine kinase (BTK) plays a vital role in B-cell functions, including differentiation, proliferation and survival, and has emerged as a critical therapeutic target of several generations of kinase inhibitors.
Adrian Schmidt
doaj   +1 more source

Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia

Annals of Hematology
The phase III BRUIN CLL-313 and CLL-314 trials have established pirtobrutinib, a noncovalent Bruton tyrosine kinase (BTK) inhibitor, as a candidate for first-line therapy in chronic lymphocytic leukemia (CLL), and all-lines regulatory approval has now ...
Boyi Chen, Shenxian Qian
doaj   +1 more source